SEATTLE, Wash., April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will participate in two upcoming investor conferences in April 2023.
22nd Annual Needham Virtual Healthcare Conference
Type: Fireside Chat
Tuesday, April 18, 2023
3:45 p.m. ET (12:45 p.m. PT)
Stifel 2023 Targeted Oncology Days (Virtual)
Type: Corporate Presentation
Wednesday, April 26, 2023
1:00 p.m. ET (10:00 a.m. PT)
A link to the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations.
About CTI BioPharma Corp.
CTI BioPharma is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product, VONJO® (pacritinib), a JAK2, ACVR1, and IRAK1 inhibitor, that spares JAK1. VONJO is approved for the treatment of adults with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. For more information, please visit www.ctibiopharma.com.
VONJO® is a registered trademark of CTI BioPharma Corp.
Investor Relations and Media Contacts:
Remy Bernarda
Jenny Kobin
invest@ctibiopharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-participate-in-two-upcoming-investor-conferences-in-april-2023-301796072.html
SOURCE CTI BioPharma Corp.
